Skip to main content
Evidence Snapshot

Leishmania amazonensis

CHEMBL612877 ORGANISM Leishmania amazonensis
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612877
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Leishmania amazonensis as ChEMBL target CHEMBL612877. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Leishmania amazonensis
ORGANISM · Leishmania amazonensis
As of 2026-09-13
ChEMBL target ID
CHEMBL612877
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Leishmania amazonensis matters

As of 2026-09-13

Leishmania amazonensis is reviewed as Leishmania amazonensis; the current evidence base includes 20 approved drugs, 2231 compounds, and 687 assays, with lead potency reaching pChEMBL 9.8.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 20 approved drugs, 2231 compounds, and 687 assays for this target. The dominant activity type is IC50. CHEMBL388978 is the current potency anchor at pChEMBL 9.8.

Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 9.8).

Activity source · ChEMBL 36 via Core Engine
20 approved pChEMBL 9.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Leishmania amazonensis matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2231
Total Compounds
687
Total Assays
20
Approved Drugs
IC50: 2268.0, EC50: 171.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL388978
 9.8 IC50 —
No preferred name
CHEMBL4763675
 9.7 IC50 —
No preferred name
CHEMBL4753069
 8.3 IC50 —
No preferred name
CHEMBL2069130
 8.0 IC50 —
No preferred name
CHEMBL2069129
 7.7 IC50 —

Approved Drugs

Structure Compound First Approval
NIFURTIMOX
CHEMBL290960
 2020
MILTEFOSINE
CHEMBL125
 2014
ITRACONAZOLE
CHEMBL64391
 1992
PENTAMIDINE
CHEMBL55
 1984
KETOCONAZOLE
CHEMBL157101
 1981
AMPHOTERICIN B
CHEMBL267345
 1964
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:15Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612877